ID   LIMD1_HUMAN             Reviewed;         676 AA.
AC   Q9UGP4; Q17RQ1; Q9BQQ9; Q9NQ47;
DT   24-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   18-JUN-2025, entry version 191.
DE   RecName: Full=LIM domain-containing protein 1;
GN   Name=LIMD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=10647888; DOI=10.1007/s004399900188;
RA   Kiss H., Kedra D., Yang Y., Kost-Alimova M., Kiss C., O'Brien K.P.,
RA   Fransson I., Klein G., Imreh S., Dumanski J.P.;
RT   "A novel gene containing LIM domains (LIMD1) is located within the common
RT   eliminated region 1 (C3CER1) in 3p21.3.";
RL   Hum. Genet. 105:552-559(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11352561; DOI=10.1006/geno.2000.6498;
RA   Kiss H., Kedra D., Kiss C., Kost-Alimova M., Yang Y., Klein G., Imreh S.,
RA   Dumanski J.P.;
RT   "The LZTFL1 gene is a part of a transcriptional map covering 250 kb within
RT   the common eliminated region 1 (C3CER1) in 3p21.3.";
RL   Genomics 73:10-19(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-272 AND SER-277, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [5]
RP   FUNCTION, INTERACTION WITH RB1, SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=15542589; DOI=10.1073/pnas.0407123101;
RA   Sharp T.V., Munoz F., Bourboulia D., Presneau N., Darai E., Wang H.-W.,
RA   Cannon M., Butcher D.N., Nicholson A.G., Klein G., Imreh S., Boshoff C.;
RT   "LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at
RT   chromosome 3p21.3, binds pRB and represses E2F-driven transcription.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:16531-16536(2004).
RN   [6]
RP   INTERACTION WITH SQSTM1.
RX   PubMed=15870274; DOI=10.1128/mcb.25.10.4010-4022.2005;
RA   Feng Y., Longmore G.D.;
RT   "The LIM protein Ajuba influences interleukin-1-induced NF-kappaB
RT   activation by affecting the assembly and activity of the protein kinase
RT   Czeta/p62/TRAF6 signaling complex.";
RL   Mol. Cell. Biol. 25:4010-4022(2005).
RN   [7]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=18439753; DOI=10.1016/j.canlet.2008.03.015;
RA   Huggins C.J., Andrulis I.L.;
RT   "Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression
RT   in human breast cancers.";
RL   Cancer Lett. 267:55-66(2008).
RN   [8]
RP   INTERACTION WITH SNAI1.
RX   PubMed=18331720; DOI=10.1016/j.devcel.2008.01.005;
RA   Langer E.M., Feng Y., Zhaoyuan H., Rauscher F.J. III, Kroll K.L.,
RA   Longmore G.D.;
RT   "Ajuba LIM proteins are snail/slug corepressors required for neural crest
RT   development in Xenopus.";
RL   Dev. Cell 14:424-436(2008).
RN   [9]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18712738; DOI=10.1002/ijc.23851;
RA   Spendlove I., Al-Attar A., Watherstone O., Webb T.M., Ellis I.O.,
RA   Longmore G.D., Sharp T.V.;
RT   "Differential subcellular localisation of the tumour suppressor protein
RT   LIMD1 in breast cancer correlates with patient survival.";
RL   Int. J. Cancer 123:2247-2253(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-304; SER-421 AND SER-424, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-424, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH LATS1 AND LATS2.
RX   PubMed=20303269; DOI=10.1016/j.cub.2010.02.035;
RA   Das Thakur M., Feng Y., Jagannathan R., Seppa M.J., Skeath J.B.,
RA   Longmore G.D.;
RT   "Ajuba LIM proteins are negative regulators of the Hippo signaling
RT   pathway.";
RL   Curr. Biol. 20:657-662(2010).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH EIF4E; AGO1; AGO2;
RP   DCP2 AND DDX6.
RX   PubMed=20616046; DOI=10.1073/pnas.0914987107;
RA   James V., Zhang Y., Foxler D.E., de Moor C.H., Kong Y.W., Webb T.M.,
RA   Self T.J., Feng Y., Lagos D., Chu C.Y., Rana T.M., Morley S.J.,
RA   Longmore G.D., Bushell M., Sharp T.V.;
RT   "LIM-domain proteins, LIMD1, Ajuba, and WTIP are required for microRNA-
RT   mediated gene silencing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:12499-12504(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-272; SER-277 AND SER-421, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   FUNCTION.
RX   PubMed=21834987; DOI=10.1186/1741-7007-9-54;
RA   Bai S.W., Herrera-Abreu M.T., Rohn J.L., Racine V., Tajadura V.,
RA   Suryavanshi N., Bechtel S., Wiemann S., Baum B., Ridley A.J.;
RT   "Identification and characterization of a set of conserved and new
RT   regulators of cytoskeletal organisation, cell morphology and migration.";
RL   BMC Biol. 9:54-54(2011).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   FUNCTION, INTERACTION WITH EGLN1/PHD2; EGLN2/PHD1; EGLN3/PHD3 AND VHL, AND
RP   IDENTIFICATION IN A COMPLEX WITH CUL2; EGLN1/PHD2; VHL AND ELOB.
RX   PubMed=22286099; DOI=10.1038/ncb2424;
RA   Foxler D.E., Bridge K.S., James V., Webb T.M., Mee M., Wong S.C., Feng Y.,
RA   Constantin-Teodosiu D., Petursdottir T.E., Bjornsson J., Ingvarsson S.,
RA   Ratcliffe P.J., Longmore G.D., Sharp T.V.;
RT   "The LIMD1 protein bridges an association between the prolyl hydroxylases
RT   and VHL to repress HIF-1 activity.";
RL   Nat. Cell Biol. 14:201-208(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-272 AND SER-277, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-145 AND SER-233, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Adapter or scaffold protein which participates in the
CC       assembly of numerous protein complexes and is involved in several
CC       cellular processes such as cell fate determination, cytoskeletal
CC       organization, repression of gene transcription, cell-cell adhesion,
CC       cell differentiation, proliferation and migration. Positively regulates
CC       microRNA (miRNA)-mediated gene silencing and is essential for P-body
CC       formation and integrity. Acts as a hypoxic regulator by bridging an
CC       association between the prolyl hydroxylases and VHL enabling efficient
CC       degradation of HIF1A. Acts as a transcriptional corepressor for
CC       SNAI1- and SNAI2/SLUG-dependent repression of E-cadherin transcription.
CC       Negatively regulates the Hippo signaling pathway and antagonizes
CC       phosphorylation of YAP1. Inhibits E2F-mediated transcription, and
CC       suppresses the expression of the majority of genes with E2F1-responsive
CC       elements. Regulates osteoblast development, function, differentiation
CC       and stress osteoclastogenesis. Enhances the ability of TRAF6 to
CC       activate adapter protein complex 1 (AP-1) and negatively regulates the
CC       canonical Wnt receptor signaling pathway in osteoblasts. May act as a
CC       tumor suppressor by inhibiting cell proliferation.
CC       {ECO:0000269|PubMed:15542589, ECO:0000269|PubMed:20303269,
CC       ECO:0000269|PubMed:20616046, ECO:0000269|PubMed:21834987,
CC       ECO:0000269|PubMed:22286099}.
CC   -!- SUBUNIT: Interacts (via LIM domains) with TRAF6. Found in a complex
CC       with TRAF6, PRKCZ and SQSTM1. Interacts (via LIM domains) SNAI2/SLUG
CC       (via SNAG domain) and SCRT1 (via SNAG domain) (By similarity).
CC       Interacts with SQSTM1 and RB1. Found in a complex composed of LIMD1,
CC       VHL, EGLN1/PHD2, ELOB and CUL2. Interacts with EIF4E, AGO1, AGO2, DCP2,
CC       DDX6, LATS1, LATS2, EGLN1/PHD2, EGLN2/PHD1 and EGLN3/PHD3. Interacts
CC       (via LIM zinc-binding 2) with isoform 1 and isoform 3 of VHL. Interacts
CC       (via LIM domains) with SNAI1 (via SNAG domain). {ECO:0000250,
CC       ECO:0000269|PubMed:15542589, ECO:0000269|PubMed:15870274,
CC       ECO:0000269|PubMed:18331720, ECO:0000269|PubMed:20303269,
CC       ECO:0000269|PubMed:20616046, ECO:0000269|PubMed:22286099}.
CC   -!- INTERACTION:
CC       Q9UGP4; Q9UL18: AGO1; NbExp=3; IntAct=EBI-2652871, EBI-527363;
CC       Q9UGP4; Q9UKV8: AGO2; NbExp=11; IntAct=EBI-2652871, EBI-528269;
CC       Q9UGP4; Q13439: GOLGA4; NbExp=2; IntAct=EBI-2652871, EBI-1037845;
CC       Q9UGP4; Q9Q2G4: ORF; Xeno; NbExp=5; IntAct=EBI-2652871, EBI-6248094;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, P-body. Cell
CC       junction, adherens junction. Cell junction, focal adhesion.
CC       Note=Shuttles between cytoplasm and nucleus but is localized
CC       predominantly to the cytoplasm. Found in the nucleus but not nucleoli.
CC       Colocalizes with VCL in the focal adhesions. Down-regulation and/or
CC       elimination of its expression from the nucleus of neoplastic cells
CC       correlates strongly with poor patient prognosis and aggressive forms of
CC       breast carcinoma. Conversely, strong nuclear localization correlates
CC       with low-tumor grade and better patient prognosis.
CC   -!- TISSUE SPECIFICITY: Expressed in normal and breast cancer tissues (at
CC       protein level). Ubiquitous. {ECO:0000269|PubMed:10647888,
CC       ECO:0000269|PubMed:18712738}.
CC   -!- INDUCTION: Down-regulated in lung cancer.
CC       {ECO:0000269|PubMed:15542589}.
CC   -!- PTM: Phosphorylated during mitosis. {ECO:0000269|PubMed:18439753}.
CC   -!- SIMILARITY: Belongs to the zyxin/ajuba family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/41158/LIMD1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ132408; CAB63652.1; -; mRNA.
DR   EMBL; AJ312686; CAC35917.1; -; Genomic_DNA.
DR   EMBL; AJ297357; CAB95944.1; -; Genomic_DNA.
DR   EMBL; BC117236; AAI17237.1; -; mRNA.
DR   EMBL; BC117238; AAI17239.1; -; mRNA.
DR   CCDS; CCDS2729.1; -.
DR   RefSeq; NP_055055.1; NM_014240.3.
DR   AlphaFoldDB; Q9UGP4; -.
DR   BioGRID; 114475; 129.
DR   CORUM; Q9UGP4; -.
DR   FunCoup; Q9UGP4; 1095.
DR   IntAct; Q9UGP4; 70.
DR   MINT; Q9UGP4; -.
DR   STRING; 9606.ENSP00000273317; -.
DR   GlyCosmos; Q9UGP4; 1 site, 1 glycan.
DR   GlyGen; Q9UGP4; 7 sites, 1 O-linked glycan (7 sites).
DR   iPTMnet; Q9UGP4; -.
DR   PhosphoSitePlus; Q9UGP4; -.
DR   SwissPalm; Q9UGP4; -.
DR   BioMuta; LIMD1; -.
DR   DMDM; 47605932; -.
DR   jPOST; Q9UGP4; -.
DR   MassIVE; Q9UGP4; -.
DR   PaxDb; 9606-ENSP00000273317; -.
DR   PeptideAtlas; Q9UGP4; -.
DR   ProteomicsDB; 84252; -.
DR   Pumba; Q9UGP4; -.
DR   Antibodypedia; 29569; 215 antibodies from 28 providers.
DR   DNASU; 8994; -.
DR   Ensembl; ENST00000273317.5; ENSP00000273317.4; ENSG00000144791.10.
DR   GeneID; 8994; -.
DR   KEGG; hsa:8994; -.
DR   MANE-Select; ENST00000273317.5; ENSP00000273317.4; NM_014240.3; NP_055055.1.
DR   UCSC; uc003coq.4; human.
DR   AGR; HGNC:6612; -.
DR   CTD; 8994; -.
DR   DisGeNET; 8994; -.
DR   GeneCards; LIMD1; -.
DR   HGNC; HGNC:6612; LIMD1.
DR   HPA; ENSG00000144791; Low tissue specificity.
DR   MalaCards; LIMD1; -.
DR   MIM; 604543; gene.
DR   OpenTargets; ENSG00000144791; -.
DR   VEuPathDB; HostDB:ENSG00000144791; -.
DR   eggNOG; KOG1701; Eukaryota.
DR   GeneTree; ENSGT00940000159019; -.
DR   HOGENOM; CLU_001357_11_1_1; -.
DR   InParanoid; Q9UGP4; -.
DR   OMA; SCKEGPP; -.
DR   OrthoDB; 25414at2759; -.
DR   PAN-GO; Q9UGP4; 10 GO annotations based on evolutionary models.
DR   PhylomeDB; Q9UGP4; -.
DR   PathwayCommons; Q9UGP4; -.
DR   Reactome; R-HSA-1234176; Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha.
DR   SignaLink; Q9UGP4; -.
DR   BioGRID-ORCS; 8994; 14 hits in 1169 CRISPR screens.
DR   ChiTaRS; LIMD1; human.
DR   GeneWiki; LIMD1; -.
DR   GenomeRNAi; 8994; -.
DR   Pharos; Q9UGP4; Tbio.
DR   PRO; PR:Q9UGP4; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9UGP4; protein.
DR   Bgee; ENSG00000144791; Expressed in lower lobe of lung and 187 other cell types or tissues.
DR   ExpressionAtlas; Q9UGP4; baseline and differential.
DR   GO; GO:0005912; C:adherens junction; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000932; C:P-body; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0016442; C:RISC complex; IDA:MGI.
DR   GO; GO:0005667; C:transcription regulator complex; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003714; F:transcription corepressor activity; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0035278; P:miRNA-mediated gene silencing by inhibition of translation; IMP:UniProtKB.
DR   GO; GO:0035195; P:miRNA-mediated post-transcriptional gene silencing; IMP:MGI.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0035331; P:negative regulation of hippo signaling; IDA:UniProtKB.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0002076; P:osteoblast development; ISS:UniProtKB.
DR   GO; GO:0033962; P:P-body assembly; IMP:MGI.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IBA:GO_Central.
DR   GO; GO:0001666; P:response to hypoxia; IDA:UniProtKB.
DR   CDD; cd09352; LIM1_Ajuba_like; 1.
DR   CDD; cd09355; LIM2_Ajuba_like; 1.
DR   CDD; cd09438; LIM3_Ajuba_like; 1.
DR   FunFam; 2.10.110.10:FF:000028; LIM domain-containing protein 1; 1.
DR   FunFam; 2.10.110.10:FF:000036; LIM domain-containing protein 1; 1.
DR   FunFam; 2.10.110.10:FF:000037; LIM domain-containing protein 1; 1.
DR   Gene3D; 2.10.110.10; Cysteine Rich Protein; 3.
DR   InterPro; IPR047172; Ajuba-like.
DR   InterPro; IPR047245; Ajuba-like_LIM1.
DR   InterPro; IPR047247; Ajuba-like_LIM2.
DR   InterPro; IPR047248; Ajuba-like_LIM3.
DR   InterPro; IPR001781; Znf_LIM.
DR   PANTHER; PTHR24219:SF3; LIM DOMAIN-CONTAINING PROTEIN 1; 1.
DR   PANTHER; PTHR24219; LIM DOMAIN-CONTAINING PROTEIN JUB; 1.
DR   Pfam; PF00412; LIM; 3.
DR   SMART; SM00132; LIM; 3.
DR   SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 2.
DR   PROSITE; PS00478; LIM_DOMAIN_1; 2.
DR   PROSITE; PS50023; LIM_DOMAIN_2; 3.
DR   neXtProt; NX_Q9UGP4; -.
DR   PharmGKB; PA30385; -.
DR   TreeFam; TF320310; -.
PE   1: Evidence at protein level;
KW   Cell junction; Cytoplasm; LIM domain; Metal-binding; Nucleus;
KW   Phosphoprotein; Proteomics identification; Reference proteome; Repeat;
KW   Repressor; RNA-mediated gene silencing; Transcription;
KW   Transcription regulation; Tumor suppressor; Zinc.
FT   CHAIN           1..676
FT                   /note="LIM domain-containing protein 1"
FT                   /id="PRO_0000075801"
FT   DOMAIN          470..531
FT                   /note="LIM zinc-binding 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00125"
FT   DOMAIN          535..595
FT                   /note="LIM zinc-binding 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00125"
FT   DOMAIN          595..664
FT                   /note="LIM zinc-binding 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00125"
FT   REGION          54..134
FT                   /note="Mediates nuclear export"
FT   REGION          104..163
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          186..260
FT                   /note="Interaction with EGLN1/PHD2"
FT   REGION          189..389
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          404..442
FT                   /note="Interaction with RB1"
FT                   /evidence="ECO:0000269|PubMed:15542589"
FT   REGION          472..676
FT                   /note="Necessary for nuclear localization"
FT   COMPBIAS        201..213
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        232..242
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        243..253
FT                   /note="Gly residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        262..271
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        343..360
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         145
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         233
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         239
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:B5DEH0"
FT   MOD_RES         272
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:15144186,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         277
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:15144186,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         304
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         316
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:B5DEH0"
FT   MOD_RES         421
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         424
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   VARIANT         36
FT                   /note="G -> D (in dbSNP:rs2578662)"
FT                   /id="VAR_050147"
FT   VARIANT         415
FT                   /note="G -> R (in dbSNP:rs3733113)"
FT                   /id="VAR_021993"
SQ   SEQUENCE   676 AA;  72190 MW;  085DF06F047B49E6 CRC64;
     MDKYDDLGLE ASKFIEDLNM YEASKDGLFR VDKGAGNNPE FEETRRVFAT KMAKIHLQQQ
     QQQLLQEETL PRGSRGPVNG GGRLGPQARW EVVGSKLTVD GAAKPPLAAS TGAPGAVTTL
     AAGQPPYPPQ EQRSRPYLHG TRHGSQDCGS RESLATSEMS AFHQPGPCED PSCLTHGDYY
     DNLSLASPKW GDKPGVSPSI GLSVGSGWPS SPGSDPPLPK PCGDHPLNHR QLSLSSSRSS
     EGSLGGQNSG IGGRSSEKPT GLWSTASSQR VSPGLPSPNL ENGAPAVGPV QPRTPSVSAP
     LALSCPRQGG LPRSNSGLGG EVSGVMSKPN VDPQPWFQDG PKSYLSSSAP SSSPAGLDGS
     QQGAVPGLGP KPGCTDLGTG PKLSPTSLVH PVMSTLPELS CKEGPLGWSS DGSLGSVLLD
     SPSSPRVRLP CQPLVPGPEL RPSAAELKLE ALTQRLEREM DAHPKADYFG ACVKCSKGVF
     GAGQACQAMG NLYHDTCFTC AACSRKLRGK AFYFVNGKVF CEEDFLYSGF QQSADRCFLC
     GHLIMDMILQ ALGKSYHPGC FRCVICNECL DGVPFTVDSE NKIYCVRDYH KVLAPKCAAC
     GLPILPPEGS DETIRVVSMD RDYHVECYHC EDCGLELNDE DGHRCYPLED HLFCHSCHVK
     RLEKRPSSTA LHQHHF
//
